We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

1.
Figure 3

Figure 3. Changes in CD4+ T-Cell Count and Percentage of CD4+ T Cells after Transplantation, According to Antithymocyte Globulin Induction Status. From: Outcomes of Kidney Transplantation in HIV-Infected Recipients.

The mean (±SE) CD4+ T-cell counts and the mean (±SE) percentages of CD4+ T cells are plotted over time in Panels A and B, respectively. At year 0.2, the mean changes from baseline in numbers and percentages of CD4+ T cells were significantly greater in patients who received antithymocyte globulin induction therapy early than in those who did not (P = 0.004 and P = 0.048, respectively). After the initial drop, there was an increase in the CD4+ T-cell count (P<0.001), but the percentage of CD4+ T cells did not change significantly over time (P = 0.66).

Peter G. Stock, et al. N Engl J Med. ;363(21):2004-2014.
2.
Figure 2

Figure 2. Kaplan–Meier Estimates of Patient and Graft Survival and First Acute Kidney-Allograft Rejection According to Presence or Absence of Hepatitis C Virus (HCV) Infection. From: Outcomes of Kidney Transplantation in HIV-Infected Recipients.

Panel A shows the rate of patient survival, Panel B the rate of graft survival, and Panel C the rate of rejection according to HCV status. Seven deaths occurred among 122 HCV-negative patients (6%) and 4 among 28 HCV-positive patients (14%). Among HCV-positive recipients, the 1-year product-limit estimates for patient survival and graft survival were 88.3% (95% CI, 67.9 to 96.1) and 88.6% (95% CI, 68.6 to 96.2), respectively. Among HCV-negative recipients, the corresponding estimates were 96.1% (95% CI, 90.0 to 98.5) and 90.9% (95% CI, 83.7 to 95.0). The hazard of death was marginally higher in the HCV-positive patients than in the HCV-negative patients (P = 0.09 by the log-rank test) (Panel A). Time-to-event curves for graft loss (Panel B) and for graft rejection (Panel C) did not differ significantly between HCV-positive and HCV-negative patients (P = 0.91 and P = 0.36, respectively, by the log-rank test).

Peter G. Stock, et al. N Engl J Med. ;363(21):2004-2014.
3.
Figure 1

Figure 1. Kaplan–Meier Estimates of Patient and Graft Survival and First Acute Kidney-Allograft Rejection. From: Outcomes of Kidney Transplantation in HIV-Infected Recipients.

Rates of patient survival (Panel A) and graft survival (Panel B) were generally within those rates reported in the national Scientific Registry of Transplant Recipients (SRTR) for older kidney-transplant recipients (≥65 years) and for all kidney-transplant recipients in the United States during a similar time frame. The rate of graft survival was calculated on the basis of graft failure from any cause. The 1-year and 3-year cumulative incidences of graft rejection in the study recipients were 31% (95% confidence interval [CI], 24 to 40) and 41% (95% CI, 32 to 52), respectively. The 1-year SRTR rejection rate was estimated to be 12.3% (95% CI, 11.9 to 12.7) (Panel C).

Peter G. Stock, et al. N Engl J Med. ;363(21):2004-2014.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk